CoChat

Pharmacotherapy and psychotherapy for body dysmorphic disorder

Open access
Ipser, Jonathan C, Sander, Candice, Stein, Dan J · 2009 · Cochrane Database of Systematic Reviews
Cited by 152

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Body dysmorphic disorder (BDD) is a prevalent and disabling preoccupation with a slight or imagined defect in appearance. Trials have investigated the use of serotonin reuptake inhibitors (SRIs) and cognitive behaviour therapy (CBT) for BDD. OBJECTIVES: To assess the efficacy of pharmacotherapy, psychotherapy or a combination of both treatment modalities for body dysmorphic disorder. SEARCH STRATEGY: We searched the Cochrane Depression, Anxiety and Neurosis Trial Register (December 2007), the Cochrane Central Register of Controlled Trials (The Cochrane Library Issue 4, 2007), MEDLINE (January 1966 to December 2007), and PsycINFO (1967 to December 2007). Ongoing and unpublished trials were located through searching the metaRegister of Controlled Trials, the CRISP and WHO ICTRP search portals (databases searched in December 2007), and through contacting key researchers and pharmaceutical companies. Additional studies were located through study reference lists. SELECTION CRITERIA: Randomised controlled trials (RCTs) of patients meeting DSM or ICD diagnostic criteria for BDD, in which the trials compare pharmacotherapy, psychotherapy or multi-modal treatment groups with active or non-active control groups. Short or long-term trials were eligible. DATA COLLECTION AND ANALYSIS: Two review authors independently assessed RCTs for inclusion in the review, collated trial data, and assessed trial quality. Investigators were contacted to obtain missing data. Summary effect sizes for dichotomous and continuous outcomes were calculated using a random effects model and heterogeneity was assessed. MAIN RESULTS: Two pharmacotherapy and three psychotherapy trials were eligible for inclusion in the review, with data from four short-term RCTs (169 participants) available for analysis. Response data from a single placebo-controlled trial of fluoxetine suggested overall superiority of medication relative to placebo (relative risk (RR) 3.07, 95% CI 1.4 to 6.72, n = 67). Symptom severity was also significantly reduced in the RCTs of fluoxetine and clomipramine (relative to desipramine), as well as in the two CBT trials (WMD -44.96, 95% CI -54.43 to -35.49, n = 73). A low relapse rate (4/22) was demonstrated in one trial of CBT. AUTHORS' CONCLUSIONS: Results from the small number of available RCTs suggest that SRIs and CBT may be useful in treating patients with BDD. The findings of these studies need to be replicated. In addition, future controlled studies in other samples, such as adolescents, and using other selective SRIs, as well as a range of psychological therapy approaches and modalities (alone and in combination), are essential in supplementing the sparse data currently available.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/14651858.cd005332.pub2

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 68

  1. Hollander, 1999, Clomipramine vs des ipramine crossover trial in body dysmorphic disorder, Archives of General Psychiatry, 56, 1033, 10.1001/archpsyc.56.11.1033 · DOI · Paper page
  2. McKay, 1999, Two-year follow-up of behavioral treatment and maintenance for body dysmorphic disorder, Behavior Modification, 23, 620, 10.1177/0145445599234006 · DOI · Paper page
  3. McKay, 1997, Body dysmorphic disorder: A preliminary evaluation of treatment and maintenance using exposure with response prevention, Behaviour Research and Therapy, 35, 67, 10.1016/S0005-7967(96)00082-4 · DOI
  4. Phillips, 2004, Change in psychosocial functioning and quality of life of patients with body dysmorphic disorder treated with fluoxetine: A placebo-controlled study, Psychosomatics, 45, 438, 10.1176/appi.psy.45.5.438 · DOI
  5. Phillips, 2002, A randomized placebo-controlled trial of fluoxetine in body dysmorphic disorder, Archives of General Psychiatry, 59, 381, 10.1001/archpsyc.59.4.381 · DOI · Paper page
  6. Veale, 1996, Body dysmorphic disorder: A cognitive behavioural model and pilot randomised controlled trial, Behavioural Research and Therapy, 34, 717, 10.1016/0005-7967(96)00025-3 · DOI · Paper page
  7. Allen, 2008, An open-label trial of venlafaxine in body dysmorphic disorder, CNS Spectr ums, 13, 138, 10.1017/S1092852900016291 · DOI
  8. Campisi, 1995, Exposure and response prevention in the treatment of body dysmorphic disorder, Dissertations Abstracts International: Section B: The Sciences and Engineering, 56, 7036
  9. Geremia, 2001, Cognitive therapy in the treatment of body dysmorphic disorder, Clinical Psychology and Psychotherapy, 8, 243, 10.1002/cpp.284 · DOI
  10. Gomez-Perez, 1994, Dysmorphobia: Clinical features and outcome with behaviour therapy, European Psychiatry, 9, 229, 10.1017/S0924933800003564 · DOI
  11. Khemlani-Patel, 2001, Cognitive and behaviour therapy for body dysmorphic disorder: A comparative investigation, Dissertation Abstracts International: Section B: The Sciences and Engineering, 62, 1087
  12. Neziroglu, 1993, Body dysmorphic disorder: phenomenology and case descriptions, Behavioural Psychotherapy, 21, 27, 10.1017/S0141347300017778 · DOI · Paper page
  13. Neziroglu, 1996, Effects of cognitive behavior therapy on persons with body dysmorphic disorder and comorbid axis II diagnoses, Behavior Therapy, 27, 67, 10.1016/S0005-7894(96)80036-0 · DOI
  14. Perugi, 1996, Fluvoxamine in the treatment of body dysmorphic disorder, International Clinical Psychopharmacology, 11, 274, 10.1097/00004850-199612000-00006 · DOI · Paper page
  15. Phillips, 1996, An open study of buspirone augmentation of serotonin-reuptake inhibitors in body dysmorphic disorder, Psychopharmacology Bulletin, 32, 175
  16. Phillips, 1998, Efficacy and safety of fluvoxamine in body dysmorphic disorder, Journal of Clinical Psychiatry, 59, 165, 10.4088/JCP.v59n0404 · DOI · Paper page
  17. Phillips, 2001, Delusionality and response in open-label fluvoxamine in body dysmorphic disorder, Journal of Clinical Psychiatry, 62, 87, 10.4088/JCP.v62n0203 · DOI · Paper page
  18. Phillips, 2003, An open-label study of citalopram in body dysmorphic disorder, Journal of Clinical Psychiatry, 64, 715, 10.4088/JCP.v64n0615 · DOI · Paper page
  19. Phillips, 2005, Placebo-controlled study of pimozide augmentation of fluoxetine in body dysmorphic disorder, American Journal of Psychiatry, 162, 377, 10.1176/appi.ajp.162.2.377 · DOI · Paper page
  20. Phillips, 2005, Olanzapine augmentation of fluoxetine in body dysmorphic disorder, American Journal of Psychiatry, 162, 1022, 10.1176/appi.ajp.162.5.1022-a · DOI
  21. Phillips, 2006, An open-label study of escitalopram in body dysmorphic disorder, International Clinical Psychopharmacology, 21, 177, 10.1097/01.yic.0000194378.65460.ef · DOI · Paper page
  22. Wilhelm, 1999, Cognitive behavior group therapy for body dysmorphic disorder: a case series, Behaviour Research and Therapy, 37, 71, 10.1016/S0005-7967(98)00109-0 · DOI
  23. American Psychiatric Association, 1987, Diagnostic and Statistical Manual of Mental Disorders
  24. American Psychiatric Association, 1994, Diagnostic and statistical manual of mental disorders
  25. Beck, 1987, Beck Depression Inventory: Manual
  26. Bohne, 2002, Prevalence of body dysmorphic disorder in a German college student sample, Psychiatry Res earch, 109, 101, 10.1016/S0165-1781(01)00363-8 · DOI · Paper page
  27. Bohne, 2002, Prevalence of symptoms of body dysmorphic disorder and its correlates: a cross-cultural comparison, Psychosomatics, 43, 486, 10.1176/appi.psy.43.6.486 · DOI · Paper page
  28. Deckersbach, 2000, Characteristics of memory dysfunction in body dysmorphic disorder, Journal of the International Neuropsychological Society, 6, 673, 10.1017/S1355617700666055 · DOI · Paper page
  29. Deeks, 2008, Analysing and presenting results
  30. Eisen, 2004, Insight in obsessive compulsive disorder and body dysmorphic disorder, Comprehensive Psychiatry, 45, 10, 10.1016/j.comppsych.2003.09.010 · DOI · Paper page
  31. Faravelli, 1997, Epidemiology of somatoform disorders: A community survey in Florence, Social Psychiatry and Psychiatric Epidemiology, 32, 24, 10.1007/BF00800664 · DOI · Paper page
  32. Feusner, 2007, Visual information processing of faces in body dysmorphic disorder, Archives of General Psychiatry, 64, 1417, 10.1001/archpsyc.64.12.1417 · DOI · Paper page
  33. Foa, 1995, DSM-IV field trial: obsessive-compulsive disorder, American Journal of Psychiatry, 152, 90
  34. Frare, 2004, Obsessive-compulsive disorder and body dysmorphic disorder: a comparison of clinical features, European Psychiatry, 19, 292, 10.1016/j.eurpsy.2004.04.014 · DOI · Paper page
  35. Gabbay, 2003, New onset of body dysmorphic disorder following frontotemporal lesion, Neurology, 61, 123, 10.1212/01.WNL.0000069607.30528.D5 · DOI
  36. Gury, 1999, Pharmacokinetics of SSRI antidepressants: half-life and clinical applicability, Encephale, 25, 470
  37. Guy, 1976, ECDEU assessment manual for psychopharmacology
  38. Higgins, 2003, Measuring inconsistency in meta-analyses, British Medical Journal, 327, 557, 10.1136/bmj.327.7414.557 · DOI · Paper page
  39. Hollander, 1989, Treatment of body-dysmorphic disorder with serotonin reuptake blockers, American Journal of Psychiatry, 146, 768, 10.1176/ajp.146.6.768 · DOI · Paper page
  40. Hollander, 1993, Body image and experience disorders: Body dysmorphic and depersonalization disorders, 17
  41. JC Ipser, 2006, Pharmacotherapy augmentation strategies in treatment-resistant anxiety disorders, Cochrane Database of Systematic Reviews
  42. Leon, 1999, The Range of Impaired Functioning Tool (LIFE-RIFT): a brief measure of functional impairment, Psychological Medicine, 29, 869, 10.1017/S0033291799008570 · DOI · Paper page
  43. Marks, 1988, Dysmorphophobic avoidance with disturbed bodily perception: A pilot study of exposure therapy, British Journal of Psychiatry, 152, 674, 10.1192/bjp.152.5.674 · DOI · Paper page
  44. McKay, 1999, Two-year follow-up of behavioral treatment and maintenance for body dysmorphic disorder, Behavior Modification, 23, 620, 10.1177/0145445599234006 · DOI · Paper page
  45. Montgomery, 1979, A new depression scale designed to be sensitive to change, British Journal of Psychiatry, 134, 382, 10.1192/bjp.134.4.382 · DOI · Paper page
  46. National Institute for Clinical Excellence, 2005, The management of post traumatic stress disorder in primary and secondary care
  47. Phillips, 1991, Body dysmorphic disorder: The distress of imagined ugliness, American Journal of Psychiatry, 148, 1138, 10.1176/ajp.148.9.1138 · DOI · Paper page
  48. Phillips, 1993, Body dysmorphic disorder: 30 cases of imagined ugliness, American Journal of Psychiatry, 150, 302, 10.1176/ajp.150.2.302 · DOI · Paper page
  49. Phillips, 1994, A comparison of delusional and nondelusional body dysmorphic disorder in 100 cases, Psychopharmacology Bulletin, 30, 179
  50. Phillips, 1997, Gender differences in body dysmorphic disorder, Journal of Nervous and Mental Disease, 185, 570, 10.1097/00005053-199709000-00006 · DOI · Paper page
  51. Phillips, 1997, A severity rating scale for body dysmorphic disorder: Development, reliability and validity of a modified version of the Yale-Brown Obsessive Compulsive Scale, Psychopharmacology Bulletin, 33, 17
  52. Phillips, 2000, Rate of body dysmorphic disorder in dermatology patients, Journal of the American Academy of Dermatology, 42, 436, 10.1016/S0190-9622(00)90215-9 · DOI · Paper page
  53. Phillips, 2001, Effectiveness of pharmacotherapy for body dysmorphic disorder: A chart-review study, Journal of Clinical Psychiatry, 62, 721, 10.4088/JCP.v62n0910 · DOI · Paper page
  54. Phillips, 2004, Change in psychosocial functioning and quality of life of patients with body dysmorphic disorder treated with fluoxetine: A place-controlled study, Psychosomatics, 45, 438, 10.1176/appi.psy.45.5.438 · DOI
  55. Phillips, 2006, Delusional versus nondelusional body dysmorphic disorder: Clinical features and course of illness, Journal of Psychiatric Research, 40, 95, 10.1016/j.jpsychires.2005.08.005 · DOI
  56. Phillips, 2006, Associations in the longitudinal course of body dysmorphic disorder with major depression, obsessive-compulsive disorder, and social phobia, Journal of Psychiatric Research, 40, 360, 10.1016/j.jpsychires.2005.10.001 · DOI
  57. Phillips, 2006, Delusional versus nondelusional body dysmorphic disorder: clinical features and course of illness, Journal of Psychiatric Resear ch, 40, 95, 10.1016/j.jpsychires.2005.08.005 · DOI
  58. Rauch, 2003, A preliminary morphometric magnetic resonance imaging study of regional brain volumes in body dysmorphic disorder, Psychiatry Research, 122, 13, 10.1016/S0925-4927(02)00117-8 · DOI
  59. Rosen, 1996, Development of the Body Dysmorphic Disorder Examination, Behaviour Research and Therapy, 34, 755, 10.1016/0005-7967(96)00024-1 · DOI · Paper page
  60. Rosen, 1998, A comparison of eating disorders and body dysmorphic disorders on body image and psychological adjustment, Journal of Psychosomatic Research, 44, 441, 10.1016/S0022-3999(97)00269-9 · DOI · Paper page
  61. Saxena, 2001, A retrospective review of clinical characteristics and treatment response in body dysmorphic disorder versus obsessive-compulsive disorder, Journal of Clinical Psychiatry, 62, 67, 10.4088/JCP.v62n0114b · DOI
  62. Schneier, 1994, Functional impairment in social phobia, J ournal of Clin ical Psychiatry, 55, 322
  63. Spitzer, 1996, Instructional manual for the structured clinical interview for DSM-IV.
  64. Veale, 1996, Body dysmorphic disorder: A survey of fifty cases, British Journal of Psychiatry, 169, 196, 10.1192/bjp.169.2.196 · DOI · Paper page
  65. Ware, 1993, SF-36 Health Survey Manual and Interpretation Guide
  66. World Health Organisation, 1975, The ICD-9 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines
  67. World Health Organisation, 1992, ICD-10 International statistical classification of diseases and related health problems : based on the International Statistical Classification of Diseases and Related Health Problems, ICD
  68. Williams, 2006, A meta-analysis of psychological and pharmacological treatments for Body Dysmorphic Disorder, Beha viour Research and Therapy, 44, 99, 10.1016/j.brat.2004.12.006 · DOI · Paper page

Cited by

See all 152

Metadata

Authors
Ipser, J. C., Sander, C., & Stein, D. J.
Venue
Cochrane Database of Systematic Reviews
Publisher
Wiley
Published
2009-01-21
Issue
1
Pages
CD005332-CD005332
ISSN
  • 1361-6137 (ISSN-L)
  • 1465-1858
OpenAlex
W2138759993
Cited by
152
References
21
FWCI
12.83
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.